<div id="readability-page-1"><div><p><span>BCIP Life Sciences Associates LP, Beneficial Owner of NewAmsterdam Pharma Co NV [NAMS], filed a Form 144 on December 2, 2025 with the Securities and Exchange Commission proposing to sell restricted securities:</span></p><div><table><tbody><tr><td><span>Approximate Date Of Sale</span></td><td><span>12/2/25</span></td></tr><tr><td><span>Shares</span></td><td><span>32,571</span></td></tr><tr><td><span>Broker</span></td><td><span>Goldman Sachs &amp; Co</span></td></tr></tbody></table></div><p><span>Prior to the sale of restricted stock, owners must file a Form 144 with the SEC.  Upon submission of the filing to the SEC the owner is permitted to sell the shares, or any fraction thereof, within 90 days.</span></p><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

NAMS

<p>BCIP Life Sciences Associates LP, a beneficial owner of NewAmsterdam Pharma Co NV, filed a Form 144 with the SEC to sell 32,571 restricted shares on December 2, 2025. The sale will be brokered by Goldman Sachs & Co. Filing Form 144 allows the owner to sell shares within 90 days. The Washington Service offers insider trading analysis and data services.</p>

Owner BCIP Life Sciences Associates LP Files To Sell 32,571 Of NewAmsterdam Pharma Co NV [NAMS]